# Radian Group Inc: financial statements, quarterly

RDN · NYSE · CIK 890926 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rdn.md) · [Financials](/companies/rdn/financials.md) · [Filings](/companies/rdn/filings.md) · [Insiders](/companies/rdn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rdn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [313](/filings/0000950170-24-122809.md) | [265 d](/filings/0001193125-26-061383.md) | [302](/filings/0001193125-26-061383.md) | [299](/filings/0001193125-26-061383.md) | [313](/filings/0001193125-26-061383.md) | [293](/filings/0001193125-26-061383.md) | [295](/filings/0001193125-26-215018.md) | [299](/filings/0001193125-26-340290.md) | [303](/filings/0001193125-26-061383.md) | [301](/filings/0001193125-26-061383.md) | [466](/filings/0001193125-26-215018.md) | [575](/filings/0001193125-26-340290.md) |
| Cost of revenue | $m | [8.9](/filings/0000950170-24-122809.md) | [9.0 d](/filings/0000950170-25-021241.md) | [9.3](/filings/0000950170-25-062800.md) | [9.5](/filings/0000950170-25-101425.md) | [9.5](/filings/0000950170-24-122809.md) | [9.9 d](/filings/0000950170-25-021241.md) | [8.8](/filings/0000950170-25-062800.md) | [8.4](/filings/0000950170-25-101425.md) | not reported | not reported | not reported | not reported |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [23.3](/filings/0000950170-24-122809.md) | [19.7 d](/filings/0001193125-26-061383.md) | [29.0](/filings/0000950170-25-062800.md) | [27.1](/filings/0000950170-25-101425.md) | [21.9](/filings/0001193125-25-269668.md) | [16.6 d](/filings/0001193125-26-061383.md) | [16.5](/filings/0001193125-26-215018.md) | [17.4](/filings/0001193125-26-340290.md) | [17.2](/filings/0001193125-25-269668.md) | [17.2 d](/filings/0001193125-26-061383.md) | [20.6](/filings/0001193125-26-215018.md) | [22.3](/filings/0001193125-26-340290.md) |
| Income tax | $m | [44.4](/filings/0000950170-24-122809.md) | [60.8 d](/filings/0001193125-26-061383.md) | [46.3](/filings/0000950170-25-062800.md) | [36.2](/filings/0000950170-25-101425.md) | [47.8](/filings/0001193125-25-269668.md) | [46.6 d](/filings/0001193125-26-061383.md) | [46.6](/filings/0001193125-26-215018.md) | [38.3](/filings/0001193125-26-340290.md) | [45.9](/filings/0001193125-25-269668.md) | [42.2 d](/filings/0001193125-26-061383.md) | [44.2](/filings/0001193125-26-215018.md) | [32.5](/filings/0001193125-26-340290.md) |
| Net income | $m | [157](/filings/0000950170-24-122809.md) | [143 d](/filings/0001193125-26-061383.md) | [152](/filings/0001193125-26-061383.md) | [152](/filings/0001193125-26-061383.md) | [152](/filings/0001193125-26-061383.md) | [148](/filings/0001193125-26-061383.md) | [145](/filings/0001193125-26-215018.md) | [142](/filings/0001193125-26-340290.md) | [141](/filings/0001193125-26-061383.md) | [155](/filings/0001193125-26-061383.md) | [124](/filings/0001193125-26-215018.md) | [116](/filings/0001193125-26-340290.md) |
| Diluted EPS | $ per share | [0.98](/filings/0000950170-24-122809.md) | not reported | [0.98](/filings/0001193125-26-061383.md) | [0.98](/filings/0001193125-26-061383.md) | [0.99](/filings/0001193125-26-061383.md) | [0.98](/filings/0001193125-26-061383.md) | [0.98](/filings/0001193125-26-215018.md) | [1.02](/filings/0001193125-26-340290.md) | [1.03](/filings/0001193125-26-061383.md) | [1.12](/filings/0001193125-26-061383.md) | [0.89](/filings/0001193125-26-215018.md) | [0.85](/filings/0001193125-26-340290.md) |
| Basic EPS | $ per share | [0.99](/filings/0000950170-24-122809.md) | not reported | [0.99](/filings/0001193125-26-061383.md) | [0.99](/filings/0001193125-26-061383.md) | [1.00](/filings/0001193125-26-061383.md) | [0.99](/filings/0001193125-26-061383.md) | [0.99](/filings/0001193125-26-215018.md) | [1.03](/filings/0001193125-26-340290.md) | [1.04](/filings/0001193125-26-061383.md) | [1.13](/filings/0001193125-26-061383.md) | [0.90](/filings/0001193125-26-215018.md) | [0.85](/filings/0001193125-26-340290.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.1](/filings/0000890926-23-000058.md) | [0.0](/filings/0000950170-25-021241.md) | [0.0](/filings/0000890926-24-000028.md) | [0.0](/filings/0000890926-24-000035.md) | [0.0](/filings/0000950170-24-122809.md) | [0.0](/filings/0001193125-26-061383.md) | [0.0](/filings/0000950170-25-062800.md) | [0.0](/filings/0000950170-25-101425.md) | [0.0](/filings/0001193125-25-269668.md) | [0.0](/filings/0001193125-26-340290.md) | [0.1](/filings/0001193125-26-215018.md) | [0.1](/filings/0001193125-26-340290.md) |
| Total assets | $bn | [7.4](/filings/0000890926-23-000058.md) | [7.6](/filings/0000950170-25-021241.md) | [7.8](/filings/0000890926-24-000028.md) | [8.1](/filings/0000890926-24-000035.md) | [8.4](/filings/0000950170-24-122809.md) | [8.7](/filings/0001193125-26-061383.md) | [8.8](/filings/0000950170-25-062800.md) | [9.6](/filings/0000950170-25-101425.md) | [8.2](/filings/0001193125-25-269668.md) | [8.1](/filings/0001193125-26-340290.md) | [10.7](/filings/0001193125-26-215018.md) | [10.7](/filings/0001193125-26-340290.md) |
| Total liabilities | $bn | [3.2](/filings/0000890926-23-000058.md) | [3.2](/filings/0000950170-25-021241.md) | [3.3](/filings/0000890926-24-000028.md) | [3.6](/filings/0000890926-24-000035.md) | [3.7](/filings/0000950170-24-122809.md) | [4.1](/filings/0001193125-26-061383.md) | [4.2](/filings/0000950170-25-062800.md) | [5.1](/filings/0000950170-25-101425.md) | [3.6](/filings/0001193125-25-269668.md) | [3.3](/filings/0001193125-26-340290.md) | [5.8](/filings/0001193125-26-215018.md) | [5.8](/filings/0001193125-26-340290.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1.1](/filings/0001193125-26-340290.md) | [0.8](/filings/0001193125-26-215018.md) | [0.7](/filings/0001193125-26-340290.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-340290.md) | [0.5](/filings/0001193125-26-215018.md) | [0.5](/filings/0001193125-26-340290.md) |
| Shareholders' equity | $bn | [4.2](/filings/0000950170-24-122809.md) | [4.4](/filings/0001193125-26-061383.md) | [4.4](/filings/0000950170-25-062800.md) | [4.5](/filings/0000950170-25-101425.md) | [4.7](/filings/0001193125-25-269668.md) | [4.6](/filings/0001193125-26-061383.md) | [4.6](/filings/0001193125-26-215018.md) | [4.5](/filings/0001193125-26-340290.md) | [4.7](/filings/0001193125-25-269668.md) | [4.8](/filings/0001193125-26-340290.md) | [4.8](/filings/0001193125-26-215018.md) | [4.8](/filings/0001193125-26-340290.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [75.2 d](/filings/0000950170-24-122809.md) | [265 d](/filings/0001193125-26-061383.md) | [51.0](/filings/0000950170-25-062800.md) | [(207) d](/filings/0000950170-25-101425.md) | [(238) d](/filings/0001193125-25-269668.md) | [(269) d](/filings/0001193125-26-061383.md) | [67.8](/filings/0001193125-26-215018.md) | [(713) d](/filings/0001193125-26-340290.md) | [358 d](/filings/0001193125-25-269668.md) | [407 d](/filings/0001193125-26-061383.md) | [285](/filings/0001193125-26-215018.md) | [343 d](/filings/0001193125-26-340290.md) |
| Capital expenditure | $m | [4.3 d](/filings/0000950170-24-122809.md) | [(5.9) d](/filings/0001193125-26-061383.md) | [1.6](/filings/0000950170-25-062800.md) | [1.1 d](/filings/0000950170-25-101425.md) | [(1.2) d](/filings/0001193125-25-269668.md) | [0.2 d](/filings/0001193125-26-061383.md) | [1.1](/filings/0001193125-26-215018.md) | [1.2 d](/filings/0001193125-26-340290.md) | [1.0 d](/filings/0001193125-25-269668.md) | [0.9 d](/filings/0001193125-26-061383.md) | [0.7](/filings/0001193125-26-215018.md) | [0.2 d](/filings/0001193125-26-340290.md) |
| Dividends paid | $m | [35.8 d](/filings/0000950170-24-122809.md) | [34.9 d](/filings/0001193125-26-061383.md) | [37.6](/filings/0000950170-25-062800.md) | [40.5 d](/filings/0000950170-25-101425.md) | [37.2 d](/filings/0001193125-25-269668.md) | [36.7 d](/filings/0001193125-26-061383.md) | [37.3](/filings/0001193125-26-215018.md) | [38.6 d](/filings/0001193125-26-340290.md) | [34.8 d](/filings/0001193125-25-269668.md) | [34.9 d](/filings/0001193125-26-061383.md) | [35.3](/filings/0001193125-26-215018.md) | [37.3 d](/filings/0001193125-26-340290.md) |
| Share repurchases | $m | [50.0 d](/filings/0000950170-24-122809.md) | [63.3 d](/filings/0001193125-26-061383.md) | [50.0](/filings/0000950170-25-062800.md) | [50.0 d](/filings/0000950170-25-101425.md) | [49.0 d](/filings/0001193125-25-269668.md) | [76.0 d](/filings/0001193125-26-061383.md) | [209](/filings/0001193125-26-215018.md) | [223 d](/filings/0001193125-26-340290.md) | [0.0 d](/filings/0001193125-25-269668.md) | [0.0 d](/filings/0001193125-26-061383.md) | [50.0](/filings/0001193125-26-215018.md) | [80.3 d](/filings/0001193125-26-340290.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [161](/filings/0000890926-24-000035.md) | [160](/filings/0000950170-24-122809.md) | [156](/filings/0001193125-26-061383.md) | [154](/filings/0001193125-26-061383.md) | [153](/filings/0001193125-26-061383.md) | [152](/filings/0001193125-26-061383.md) | [148](/filings/0001193125-26-215018.md) | [138](/filings/0001193125-26-340290.md) | [138](/filings/0001193125-26-061383.md) | [138](/filings/0001193125-26-061383.md) | [138](/filings/0001193125-26-215018.md) | [136](/filings/0001193125-26-340290.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 132,301,318 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340290.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.